Tolerability of first-line therapy for metastatic renal cell carcinoma.
about
Interventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaFatigue in renal cell carcinoma: the hidden burden of current targeted therapiesDevelopment and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.Optimizing treatment for metastatic renal cell carcinoma.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Renal effects of targeted anticancer therapies.Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.The potential of virus-based gene therapies for treatment of metastatic kidney cancer.Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma.Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.
P2860
Q24187823-FED2C35A-B046-4235-96C3-6A638B8CEA7CQ24235777-B80D9F39-5ABB-4B64-90DF-AA591C683481Q28066747-C63D5C1B-8779-473B-B731-0FE16E605093Q35583812-A42CDDE7-7855-4C5E-A631-5C97316E96BFQ35602130-A9594D76-6929-4612-BD75-25AE37FBC008Q37683755-B6252C32-8751-49CD-8FAA-FB543E67F69BQ37830778-E0B7F997-9940-4D0A-BCFA-F8BF35C72A1BQ37895254-0D5E5698-2416-4664-834C-EA25BD63A3EBQ37960915-8265FC2E-4850-48BF-BC8B-866243C9C440Q37974894-0CDA2C92-2DDD-4744-A386-1109E08D2221Q38367168-3CAF48B2-584D-4EE4-B288-31838E2816C3Q42603046-DDA40A7F-A16A-4894-8644-C262EEEB5387Q45365447-3AFB4333-F32B-4588-8D8D-3798AC4A9841Q45932398-F05A3853-C73D-4BAD-A6DF-A39066B5399EQ48081321-90888F94-2C2C-4FDD-90D0-F0F32B5F14E7Q49722763-E2E35CB7-2583-4FB0-B36B-7C9FBD5B67EFQ50856966-14FD4BFD-849D-4963-9F20-BA1F46095FA1Q54634466-65BCFDC8-0DBB-47A8-A1D4-638EDFFA60A2
P2860
Tolerability of first-line therapy for metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@en
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@nl
type
label
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@en
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@nl
prefLabel
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@en
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@nl
P1476
Tolerability of first-line therapy for metastatic renal cell carcinoma.
@en
P2093
Cezary Szczylik
P304
P356
10.1016/J.CTRV.2008.12.003
P577
2009-02-26T00:00:00Z